Product

Retatrutide 30mg

Retatrutide (LY3437943) is an investigational molecule being evaluated in clinical research involving metabolic pathways. It acts on GIP, GLP-1, and glucagon receptors and remains under clinical development.

Retatrutide has not been approved by the FDA or other regulatory agencies for public use, and its safety and efficacy are still under evaluation. Lilly

Product Information

• Compound: Retatrutide
• Listed Amount: 30mg
• Research Area: Metabolic Research
• Status: Investigational
• FDA Approved: No
• Intended Presentation: Research information only

Notice:
Investigational compound. Not approved for public or therapeutic use.